Kristin Hanson, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1659379378
Payments from drug & device makers
Across 69 payments — averaging $46.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$136
- Sanofi-aventis U.S. LLC$102
- Boehringer Ingelheim$97
- Medtronic$96
- Lilly USA, LLC$80
- plus $521 from 21 others
What the payments were for
- Consulting fees$2,13066%
- Food & beverage$1,10834%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $2,208 |
| Amgen(2 entities) | 8 | $136 |
| Sanofi-aventis U.S. LLC | 7 | $102 |
| Boehringer Ingelheim | 5 | $97 |
| Medtronic(2 entities) | 5 | $96 |
| Lilly USA, LLC | 5 | $80 |
| Eton Pharmaceuticals, Inc. | 2 | $63 |
| Antares Pharma, Inc. | 3 | $52 |
| Novartis | 4 | $52 |
| Johnson & Johnson | 3 | $46 |
| Abbott | 2 | $38 |
| Corcept Therapeutics | 2 | $29 |
| Averitas Pharma Inc. | 1 | $28 |
| GSK | 2 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Vivus LLC | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Lifescan, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| AstraZeneca | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Merck | 1 | $11 |
| Travere Therapeutics, Inc. | 1 | $1 |
How this compares
$3,239 in reported general payments places this provider in the 50th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 21 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $26821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Phoenix
- Kevin YuenPhoenix$733K
- Joan BaileyPhoenix$316K
- Peter ReavenPhoenix$142K
- Sherman HarmanPhoenix$47K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- Richard ArakakiPhoenix$20K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.